Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20893475 | 0.83 | PDE10A (0.48) | MAPK8MAPK10PDE10A | |
| SCHEMBL11360192 | 0.83 | PDE10A (0.48) | MAPK8MAPK10PDE10A | |
| SCHEMBL26122808 | 0.82 | CHRM2 (0.46) | MAPK8MAPK10KDM4E | |
| SCHEMBL13622628 | 0.81 | FFAR4 (0.47) | RIPK1ADORA2A | |
| SCHEMBL460460 | 0.80 | KDM4E (0.56) | MAPK8MAPK10PDE10AKDM4EGAA | |
| SCHEMBL3929507 | 0.80 | RIPK1 (0.46) | SIGMAR1RIPK1KDM4ECYP1A2GAA | |
| SCHEMBL23327807 | 0.80 | MAPK8 (0.44) | MAPK8MAPK10PDE10AKDM4E | |
| SCHEMBL14622839 | 0.80 | ADORA2A (0.43) | SIGMAR1RIPK1ADORA2ADRD2 | |
| SCHEMBL1103982 | 0.80 | MAPK8 (0.47) | MAPK8MAPK10PDE10AKDM4E | |
| SCHEMBL8208254 | 0.79 | POLB (0.58) | MAPK8MAPK10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101657471-B | Bicyclic compounds and their use as antidiabetics | SMITHKLINE BEECHAM CORP | 2013-07-03 | — | — | CN | disclosed |
| US-20120077812-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | FANG JING (US) | 2012-03-29 | — | — | US | disclosed |
| US-8101634-B2 | Bicyclic compounds and use as antidiabetics | GLAXOSMITHKLINE LLC (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2325182-A1 | Bicyclic compounds and use as antidiabetics | Glaxosmithkline LLC (US) | 2011-05-25 | — | — | EP | disclosed |
| CN-101657471-A | Bicyclic compounds and their use as antidiabetics | SMITHKLINE BEECHAM CORP US | 2010-02-24 | — | — | CN | disclosed |
| US-20100029650-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITH KLINE BEECHAM CORPORATION a corporation | 2010-02-04 | — | — | US | disclosed |
| EP-2094683-A2 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SmithKline Beecham Corporation (US) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008070692-A2 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077812-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | GPR119, GOT2, PC | MAPK8 1710/4885MAPK10 2532/4885SIGMAR1 3676/4885 |
| US-20100029650-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | GPR119, GOT2, PC | MAPK8 1710/4885MAPK10 2532/4885SIGMAR1 3676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.